4//SEC Filing
SCHIFF ANDREW N 4
Accession 0001415889-25-016252
CIK 0001557746other
Filed
Jun 8, 8:00 PM ET
Accepted
Jun 9, 4:20 PM ET
Size
13.6 KB
Accession
0001415889-25-016252
Insider Transaction Report
Form 4
SCHIFF ANDREW N
Director
Transactions
- Award
Stock Option (Right to Buy)
2025-06-05+42,350→ 42,350 totalExercise: $1.56Exp: 2035-06-04→ Common Stock (42,350 underlying) - Exercise/Conversion
Restricted Stock Units
2025-06-06−4,793→ 0 total→ Common Stock (4,793 underlying) - Exercise/Conversion
Common Stock
2025-06-06+4,793→ 13,960 total - Award
Restricted Stock Units
2025-06-05+11,580→ 11,580 total→ Common Stock (11,580 underlying)
Holdings
- 434,455(indirect: By Aisling Capital IV LP)
Common Stock
Footnotes (6)
- [F1]Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer.
- [F2]The reportable securities are owned directly by Aisling Capital IV, LP ("Aisling"), and held indirectly by Aisling Capital Partners IV, LP ("Aisling GP"), as general partner of Aisling, Aisling Capital Partners IV LLC ("Aisling Partners"), as general partner of Aisling GP, and each of the individual managing members of Aisling Partners. The individual managing members (collectively, the "Managers") of Aisling Partners are Dr. Andrew Schiff and Steve Elms. Aisling GP, Aisling Partners, and the Managers share voting and dispositive power over the shares directly held by Aisling. Dr. Schiff disclaims beneficial ownership of these securities and this report is not an admission that he is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of his pecuniary interest therein.
- [F3]The shares subject to this stock option will vest in twelve equal monthly installments commencing on July 5, 2025, subject to the Reporting Person's Continuous Service (as defined in the Plan) through each such vesting date.
- [F4]This grant was made pursuant to the issuer's tenth amended and restated non-employee director compensation policy.
- [F5]The shares underlying these restricted stock units will vest in one installment on June 5, 2026, subject to the Reporting Person's Continuous Service (as defined in the Plan) as of such date.
- [F6]The shares underlying these restricted stock units vested on June 6, 2025.
Documents
Issuer
Aclaris Therapeutics, Inc.
CIK 0001557746
Entity typeother
Related Parties
1- filerCIK 0001172252
Filing Metadata
- Form type
- 4
- Filed
- Jun 8, 8:00 PM ET
- Accepted
- Jun 9, 4:20 PM ET
- Size
- 13.6 KB